Mechanisms of TKI-induced diarrhea in cancer patients

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 2, 2013, Pages 162-167

  Bowen, Joanne M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Diarrhea; Mechanisms; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL; CHEMICALLY INDUCED DISORDER; DIARRHEA; DISEASE MODEL; DRUG ANTAGONISM; HUMAN; NEOPLASM; PATHOPHYSIOLOGY; REVIEW; RODENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DIARRHEA; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RODENTIA;

EID: 84877961253     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32835ec861     Document Type: Review

References (50)

1. Keefe D, Anthony L. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care. Curr Opin Support Palliat Care 2008; 2: 19-21.
2. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 2008; 5: 268-278.
3. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
4. Bowen JM, Mayo BJ, Plews E, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther 2012; 13: 1269-1275.
5. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-727.
6. Roussidis AE, Karamanos NK. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment. In Vivo 2002; 16: 459-469.
7. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
8. Van Etten RA. c-Abl regulation: a tail of two lipids. Curr Biol 2003; 13:R608-R610.
9. Hubbard SR. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 464-471.
10. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
12. Templeton A, Ocana A, Seruga B, et al. Management of small HER2 overexpressing tumours. Breast Cancer Research and Treatment 2012; 136: 289-293.
13. Tsao AS, Wei W, Kuhn E, et al. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-beta) is associated with PDGFRB gene copy number gain in sarcomatoid nonsmall-cell lung cancer. Clin Lung Cancer 2011; 12: 369-374.
14. Keefe DM, Gibson RJ. Mucosal injury from targeted anticancer therapy. Support Care Cancer 2007; 15: 483-490.
15. Thomas SK, Fossella FV, Liu D, et al. Asian ethnicity as a predictor of response in patients with nonsmall-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006; 7: 326-331.
16. Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced nonsmall-cell lung cancer. Curr Oncol 2011; 18: 126-138.
17. Chen P, Wang L, Liu B, et al. EGFR-targeted therapies combined with chemotherapy for treating advanced nonsmall-cell lung cancer: a metaanalysis. Eur J Clin Pharmacol 2011; 67: 235-243.
18. Cohen EE, Halpern AB, Kasza K, et al. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2009; 45:e155-e160.
19. Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in nonsmall-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78: 8-15.
20. Crown JP, Burris HA, 3rd, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; 112: 317-325.
21. Keefe D, Bowen J, Gibson R, et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011; 16: 432-444.
22. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470-481.
23. Kirkali Z. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU Int 2011; 107: 1722-1732.
24. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011; 37: 75-88.
25. Abbas R, Hug BA, Leister C, Sonnichsen D. Adouble-blind, randomized, multipledose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol 2012; 70: 191-199.
26. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008; 26: 1119-1127.
27. Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut 2001; 48: 803-807.
28. Opleta-Madsen K, Hardin J, Gall DG. Epidermal growth factor upregulates intestinal electrolyte and nutrient transport. Am J Physiol 1991; 260 (6 Pt 1): G807-G814.
29. Goodlad RA, Raja KB, Peters TJ, Wright NA. Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity. Gut 1991; 32: 994-998.
30. Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 1993; 105: 1323-1332.
31. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009; 2009: 567486.
32. McCole DF, Barrett KE. Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function. Acta Physiol (Oxf) 2009; 195: 149-159.
33. Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol 2008; 34: 844-850.
34. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Therap 2008; 30: 1426-1447.
35. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011; 71: 443-454.
36. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35: 692-706.
37. Boerma M, Wang J, Burnett AF, et al. Local administration of interleukin-11 ameliorates intestinal radiation injury in rats. Cancer Res 2007; 67: 9501-9506.
38. Watkins B, Pouliot K, Fey E, et al. Attenuation of radiation- and chemoradiation- induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis 2010; 16: 655-660.
39. Bowen JM, Stringer AM, Gibson RJ, et al. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007; 6: 1449-1454.
40. Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004; 5: 115-120.
41. Egger B, Buchler MW, Lakshmanan J, et al. Mice harboringa defective epidermal growth factor receptor (waved-2) have an increased susceptibility to acute dextran sulfate-induced colitis. Scand J Gastroenterol 2000; 35: 1181-1187.
42. Helmrath MA, Erwin CR, Warner BW. A defective EGF-receptor in waved-2 mice attenuates intestinal adaptation. J Surg Res 1997; 69: 76-80.
43. Joshi V, Ray GS, Goldenring JR. Inhibition of parietal cell acid secretion is mediated by the classical epidermal growth factor receptor. Dig Dis Sci 1997; 42: 1194-1198.
44. Troyer KL, Luetteke NC, Saxon ML, et al. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-alpha. Gastroenterology 2001; 121: 68-78.
45. Hare KJ, Hartmann B, Kissow H, et al. The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res 2007; 13: 5170-5175.
46. Yusta B, Holland D, Koehler JA, et al. Erb Bsignalingisrequiredfortheproliferative actions of GLP-2 in the murine gut. Gastroenterology 2009; 137: 986-996.
47. Rasmussen AR, Viby NE, Hare KJ, et al. The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Dig Dis Sci 2010; 55: 2785-2796.
48. Castaneda CA, Gomez HL. Pazopanib: an antiangiogenic drug in perspective. Future Oncol 2009; 5: 1335-1348.
49. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with nonsmall cell lung cancer. Clin Pharmacol Ther 2006; 80: 136-145.
50. Li J, Karlsson MO, Brahmer J, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006; 98: 1714-1723.